No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects

BACKGROUND: Daclatasvir (DCV) is an NS5A replication complex inhibitor recently approved for chronic hepatitis C virus treatment. METHODS: To assess drug interactions between the HIV integrase strand transfer inhibitor dolutegravir (DTG) and DCV, subjects were randomized into 1 of 2 sequences in an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross, Lisa L., Song, Ivy H., Arya, Niki, Choukour, Mike, Zong, Jian, Huang, Shu-Pang, Eley, Timothy, Wynne, Brian, Buchanan, Ann M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957413/
https://www.ncbi.nlm.nih.gov/pubmed/27450277
http://dx.doi.org/10.1186/s12879-016-1629-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957413/
https://www.ncbi.nlm.nih.gov/pubmed/27450277
http://dx.doi.org/10.1186/s12879-016-1629-5

Ejemplares similares